Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

1. Potent anti-tumor activity of CD98hc-targeted antibody-drug conjugates in ovarian cancer.Signal transduction and targeted therapy · 2026
   Article
2. Therapeutic potential of photoimmunotherapy in solid tumors expressing CD98 heavy chain.Scientific reports · 2026
   Article
3. Combining radiotherapy with CAR-T cell therapy for solid tumors: Challenges, mechanisms, and future directions.Precision radiation oncology · 2026
   Review
4. Unraveling the molecular landscape: an overview on gene expression, epigenetic alterations, and therapeutic challenges in head and neck squamous cell carcinoma.Molecular genetics and genomics : MGG · 2026
   Review
5. Elevated SLC3A2 Expression Promotes the Progression of Gliomas and Enhances Ferroptosis Resistance through the AKT/NRF2/GPX4 Axis.Cancer research and treatment · 2026
   Article
6. Disruption of glutamine transport uncouples the NUPR1 stress-adaptation program and induces prostate cancer radiosensitivity.Cell communication and signaling : CCS · 2025
   Article
7. Unraveling the Role of Tumor-Infiltrating Immune Cells in Head and Neck Squamous Cell Carcinoma: Implications for Antitumor Immune Responses and Immunotherapy.International journal of molecular sciences · 2025
   Review
8. Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma.Biomarker research · 2025
   Review
9. From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors.Frontiers in immunology · 2025
   Review
10. The role of CD98 heavy chain in cancer development.Histology and histopathology · 2024
    Review
11. An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer.Journal of experimental & clinical cancer research : CR · 2023
    Article
12. Immunotargeting of Cancer Stem Cells.Cancers · 2023
    Review
13. CD98 heavy chain as a prognostic biomarker and target for cancer treatment.Frontiers in oncology · 2023
    Review
14. Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer.Frontiers in immunology · 2023
    Review
15. Combining Radiation- with Immunotherapy in Prostate Cancer: Influence of Radiation on T Cells.International journal of molecular sciences · 2022
    Article
16. Radiotherapy plus CAR-T cell therapy to date: A note for cautions optimism?Frontiers in immunology · 2022
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

14 authors at 2 institutions in 1 country.

Funding

Abstract

Indexed as